GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Cyclically Adjusted PB Ratio

Axsome Therapeutics (Axsome Therapeutics) Cyclically Adjusted PB Ratio : 34.86 (As of Jun. 07, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-07), Axsome Therapeutics's current share price is $73.90. Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.12. Axsome Therapeutics's Cyclically Adjusted PB Ratio for today is 34.86.

The historical rank and industry rank for Axsome Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

AXSM' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 32.03   Med: 37.77   Max: 48.45
Current: 35.27

During the past years, Axsome Therapeutics's highest Cyclically Adjusted PB Ratio was 48.45. The lowest was 32.03. And the median was 37.77.

AXSM's Cyclically Adjusted PB Ratio is ranked worse than
98.64% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs AXSM: 35.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Axsome Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $3.035. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.12 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Axsome Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Axsome Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Cyclically Adjusted PB Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 39.89

Axsome Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 39.89 37.65

Competitive Comparison of Axsome Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Axsome Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Cyclically Adjusted PB Ratio falls into.



Axsome Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Axsome Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=73.90/2.12
=34.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Axsome Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.035/131.7762*131.7762
=3.035

Current CPI (Mar. 2024) = 131.7762.

Axsome Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -0.252 99.070 -0.335
201503 0.000 99.621 0.000
201506 -0.407 100.684 -0.533
201509 0.220 100.392 0.289
201512 2.425 99.792 3.202
201603 2.153 100.470 2.824
201606 1.823 101.688 2.362
201609 1.471 101.861 1.903
201612 1.126 101.863 1.457
201703 1.244 102.862 1.594
201706 0.964 103.349 1.229
201709 0.712 104.136 0.901
201712 0.656 104.011 0.831
201803 0.493 105.290 0.617
201806 0.267 106.317 0.331
201809 0.028 106.507 0.035
201812 0.031 105.998 0.039
201903 0.522 107.251 0.641
201906 0.707 108.070 0.862
201909 0.198 108.329 0.241
201912 4.839 108.420 5.881
202003 4.212 108.902 5.097
202006 4.139 108.767 5.015
202009 3.622 109.815 4.346
202012 3.045 109.897 3.651
202103 2.563 111.754 3.022
202106 1.897 114.631 2.181
202109 1.133 115.734 1.290
202112 0.413 117.630 0.463
202203 0.378 121.301 0.411
202206 0.381 125.017 0.402
202209 3.624 125.227 3.814
202212 2.519 125.222 2.651
202303 2.568 127.348 2.657
202306 5.986 128.729 6.128
202309 5.696 129.860 5.780
202312 4.033 129.419 4.106
202403 3.035 131.776 3.035

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Axsome Therapeutics  (NAS:AXSM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Axsome Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (Axsome Therapeutics) Business Description

Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs director
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111

Axsome Therapeutics (Axsome Therapeutics) Headlines

From GuruFocus